Safety experience with caspofungin in pediatric patients.
We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, 1 week to 17 years of age. Caspofungin was administered for 1 to 87 (mean 12.1) days. The most common drug-related adverse events were fever, increased AST, increased ALT, and rash; few events were serious or required treatment discontinuation. Caspofungin was well tolerated in this pediatric population.
Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. zaoutis@email.chop.edu
Theoklis
T
Zaoutis
Thomas
T
Lehrnbecher
Andreas H
AH
Groll
William J
WJ
Steinbach
Hasan S
HS
Jafri
Johan
J
Maertens
Angela L
AL
Ngai
Joseph W
JW
Chow
Arlene F
AF
Taylor
Kim M
KM
Strohmaier
Michael
M
Bourque
Susan K
SK
Bradshaw
Maria
M
Petrecz
Nicholas A
NA
Kartsonis
D000293:Adolescent; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000077336:Caspofungin; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D054714:Echinocandins / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D055666:Lipopeptides; D009181:Mycoses / Q000188:drug therapy*; D011446:Prospective Studies
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077336:Caspofungin